New antiviral drug in trials скачать в хорошем качестве

New antiviral drug in trials

Novel oral antiviral for SARS-CoV-2 progresses in Phase I trial, Protease inhibitor https://www.europeanpharmaceuticalrev... Background science Viral proteases are enzymes, endopeptidases Encoded by the genetic material (DNA or RNA) of viral pathogens Catalyze cleavage of specific peptide bonds in viral precursors These proteolytic events are essential for the completion of the viral infectious cycle Protease inhibitors, bind to a viral enzyme, called a protease Prevent the virus from replicating Protease inhibitors, used to treat HIV and hepatitis C Assess tolerability and safety of multiple ascending doses of PF-07321332 Phase I study, healthy adults Randomised, double-blind, sponsor-open, placebo-controlled, single- and multiple-dose escalation study in healthy adults evaluating the safety, tolerability and pharmacokinetics of PF-07321332. Protease inhibitor, demonstrated potent in vitro antiviral activity against SARS-CoV-2 and other coronaviruses. Could be prescribed orally at the first sign of infection Pfizer also investigating an intravenously administered protease inhibitor, PF-07304814, in hospitalised patients with COVID-19. November??